Telavancin: A New Antibiotic for Complicated Skin Infections
This novel lipoglycopeptide performed as well as standard therapy in a phase II study but has the potential for nephrotoxicity and other complications.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)